Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.

@article{Sonpavde2012RandomizedPI,
  title={Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.},
  author={Guru P Sonpavde and Vsevolod B. Matveev and John M. Burke and John R Caton and Mark T. Fleming and Thomas E. Hutson and Matt D Galsky and William R. Berry and P A Karlov and Jon Holmlund and Brian A. Wood and Melissa Brookes and Lance Howard Leopold},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2012},
  volume={23 7},
  pages={1803-8}
}
BACKGROUND AT-101 (A), a small molecule oral inhibitor of the Bcl-2 family, has activity alone and in combination with docetaxel (Taxotere) and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC). A randomized, double-blind, placebo-controlled phase II trial compared DP combined with either AT-101 (A) or placebo in chemonaive mCRPC. PATIENTS AND METHODS Men with progressive mCRPC despite androgen deprivation were eligible and randomized 1:1. Patients received docetaxel… CONTINUE READING
47 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Similar Papers

Loading similar papers…